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ABStRAct                        Research in understanding the molecular basis of pain has accelerated in the last 
twenty years. Beside the description of the ‘chemical soup’ and their receptors in chronic pain, 
the cloning and role of the TRP (Transient Receptor Potential) channels was also discovered, 
making the synthesis of new agonists and antagonists possible. However the organism itself 
is able to antagonize pain by activating endogenous opioid and cannabinoid receptors. New 
pathways in pain therapy might evolve by exploring these molecular mechanisms further.
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Acute pain is useful for the organism in case of danger; 
chronic pain however can be harmful to the body. Therefore 
the former is also called physiologic, because it is basically a 
protective behaviour, whereas the latter is named  pathologic, 
or in most cases neuropathic pain, characterized by a long-
lasting time component usually after injuries or inflamma-
tions. The anatomy and physiology of pain were studied in 
detail in the last two centuries, however the thorough research 
of the molecular biology of sensory nerves and neurons 
started only in the twentieth century.
First the so called pain mediators were established, among 
them biogenic amines (histamine, serotonin), amino acids 
(glutamate), peptides (substance P, bradykinin, calcitonin 
gene related peptide (CGRP), prostaglandins, interleukins, 
cytokines, chemokines, adenine nucleotides. Later their 
metabolism and the respective receptor were investigated 
(Fig. 1). The role of ions and the molecular structure of 
voltage-gated ion channels was also an important step in 
pain physiology and pathology. Meanwhile the metabolism 
and the specific receptors of the antinociceptive endogenous 
substances like the opioid peptides and the anandamides, 
were also discovered.
Why is it so important to search the molecular background 
of pain? Because till now only symptomatic drugs existed to 
treat pain, perhaps the molecular background could help to 
find a more effective therapy.
Nonspecific ion channels
According the external stimuli pain can be divided into me-
chanical, chemical and thermal nociception. Mechanical pain 
caused by pressure or injuries is supposed to be transmitted 
by the mechanotransduction channels as Asic (acid-sensitive 
ionic channels) 1,2 and 3, but TRPA1, TRPV2 and TRPV4 
as modulators could be also included in this distribution. 
Voltage-gated potassium, sodium and calcium channels play 
an important role in the transmission of acute mechanical 
pain. Chemical noxious nociception is also transferred by the 
TRP channels (Venkatachalam et al. 2007): TRPV1 (vanillin, 
capsaicin, resiniferatoxin sensitive), TRPV4 (phorbolesters 
act as agonists), TRPA1 (isothiocyanate, mustard-oil, icilin, 
acrolein, etc.),TRPM8 (menthol reactive).Thermal nocicep-
tion  is expressed by the heat sensitive TRPV1, TRPV2, 
TRPV3 and TRPV4 channels, while cold is transduced by 
TRPM8 and TRPA1 receptors (Caterina et al.1997 and 2006; 
Julius et al. 2001; Gunthorpe et al. 2002; Clapham, 2003; 
Nagy et al. 2004; Szolcsányi et al. 2006; Abrahamsen et al. 
2008; Basbaum et al. 2009).Voltage-gated sodium and potas-
sium channels contribute with the TRP and ASIC channels to 
temperature- and mechanotransduction of pain (Wemme et al. 
2006; Zimmermann et al. 2007; Chalfie 2009).
TRP-s are non-selective cation sensitive channels, show-
ing the highest selectivity for calcium permeability. As TRP 
channels play an important role in all kinds of pain and their 
structure was investigated only since the 1990s, it seems 
worth while to take a look at their molecular construction. 
They contain six transmembrane regions, a pore-loop do-
main, an intracellular carboxyl and amino termini which 
assemble as tetramers to form cation-permeable domains. 
Their amino acid content varies from 761 till 1120. In their 
N-terminal sequence they display various numbers of ankyrin 
rings (4-14) except for TRPM8. They are supposed to play a 
role in trafficking and the formation of homo- or heteromers. 
The first cloned TRP channel was TRPV1 by Caterina et al. 
in 1997 (Fig. 2).
Sensitization of TRP channels may give rise to allodynia, 
hyperalgesia, inflammation and pain. The endogenous media-
tors of these effects could be prostaglandins, adenosine, ATP, 
serotonin, bradykinin, CGRP, NGF (Nerve growth factor), 
Substance P (see also second paragraph), but enzymes as 
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protein kinase A and C, and phospholipase C are activators 
of TRPV too (Oláh et al. 2002; Varga et al. 2006).
Desensitization of the TRP channels occurs when long-
lasting action of noxious stimuli persists. A typical example 
is the desensitization of TRPV1 channels with capsaicin or 
resiniferatoxin (Jancsó et al. 1977; Szolcsányi et al. 1990). 
External application of some of these agonists was already 
used in pain therapy in the form of plasters on the skin. A 
lot of TRPV1 inhibitors are in clinical testing phase too, 
but side effects as for example high fever in some of them, 
render their introduction in therapy difficult. Centrally acting 
inhibitors achieve a maximal action (Patapoutian et al. 2009). 
Blocking of Ca2+ penetration in most TRPV channels is also 
a possibility for pain reduction. Calmodulin is able to link 
to the C-terminal and to the first ankyrin ring amino acids, 
decreasing in such manner Ca2+ actions on TRPV1.
The application of molecular, genetic (in situ hybridiza-
tion, knockout animals) and immunological (immunohis-
tochemical and fluorescent) and cell culture methods facili-
tated the localization of TRP channels and other pain related 
receptors in the central and peripheral nervous system. The 
detailed application of these methods were able to prove the 
presence of TRPV1 and other pain receptors not only in the 
dorsal root ganglion, where they were localized first owing 
to their high concentrations, but also in the CNS, skin and 
somatic organs as well (Mezey et al. 2000). These methods 
enabled the localization of various receptors not only in the 
different organs, but also within the sensory neurons, nerve 
endings or glial cells. The liberated pain mediators from 
immune cells, mast cells, platelets and macrophages act as 
an ‘inflammatory soup’ on their specific receptors  (see also 
Fig. 1). Therefore it is not easy to inhibit some or all of them, 
without damaging their physiological role (Patapoutian et 
al. 2009).
opioid peptides, cannabinoids and 
receptors
The living organism defends itself with endogenous com-
pounds against pain. Such are the opioid peptides (endorphins, 
enkephalins, endomorphins, dynorphins, nociceptin) and the 
endogenous cannabinoids (anandamide, N-arachidonoyl-
dopamine and 2-arachidonylglycerol).
Opioid peptides act by binding to mu-, delta- and kappa-
opioid receptors. Endomorphin-1 and -2 are mu-specific, 
met- and leu-enkephalins are mu- and delta specific,-beta-
endorphin is also similarly mu- and delta specific, dynor-
phin (1-19) is kappa-opiate receptor specific (for reviews 
see Wollemann 1990; Kieffer 1995). The opiate receptors 
activate inhibitory guanine nucleotide binding proteins (G
i
), 
their effect results in blocking adenylate cyclase and protein 
kinase A. The inhibition of proteinkinase A or C results in 
a decrease of TRPV1 effect, therefore pain is diminished 
(Vetter et al. 2006). The reverse reaction, i.e. inhibition of 
Figure 1. Inflammatory mediators released at tissue injury, adapted from Julius and Basbaum (2001).
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opiate receptor mu and kappa binding by capsaicin occurs 
also in vitro and was suspended by capsazepine, but it is not 
a direct action on mu-opiod receptors, because in CHO cells 
stably expressing mu opioid receptors and lacking TRPV1, 
the inhibition of capsaicin was not present. The effect was 
exerted most probably through the activation of protein ki-
nases (Wollemann et al. 2008). In addition opiate receptors 
act through G
i
 on ion channels by increasing K+ and decreas-
ing Ca2+ conductance, which brings about the reduction of 
membrane permeability.
   The amino acid structure of opioid receptors was discov-
ered in the 1990s using cloning methods (Kieffer et al.1992). 
They contain an extracellular N-terminal and an intracellular 
C-terminal. Between them seven transmembrane regions are 
located, which include the most hydrophobic amino acids 
with the highest homology among the three opioid receptor 
types (Chen et al. 1993). The overall homology is around 60% 
(Fig. 3.). The third transmembrane region is  most important 
in drug binding, the third  intracellular region between the 





 proteins. The phosphorylations of serines and thre-
onines by protein kinase C on the C-terminal and on the third 
intracellular parts result in desensitization. The arginines in 
the N-terminal region serve as potential glycosylation sites. 
The cysteines in the opioid receptors can be palmitoylated 
which might serve as a connection to the membrane (Chen 
et al. 1998). The strongest pain inhibitory action is exerted 
across the mu receptors. The antinociceptive action of en-
dogenous opioid peptides however disappears rapidly due to 
brain peptidase enzymes.
   A Janus-faced opiate receptor like protein (OPRL) was 
the latest discovered among the opiate receptors (Meunier et 
al.1995, Reinscheid et al.1995). Its structure and peptide af-
finity resembles somewhat to the kappa-opioid receptor. The 
specific ligand nociceptin causes in low concentration anal-
gesia, but in higher amounts pronociceptive actions occurred. 
The antinociceptive action is localizable in the spinal cord, 
whereas the hyperalgesic effect is occurring supraspinally 
(Meunier 1997, Meunier et al.2000, Reinscheid et al. 1998, 
Reinscheid et al. 2000).
One of the oldest pain killing methods used first in ancient 
China was opium smoking, which had a central painkilling 
and euphoric effect. The active principle of the smoke is the 
different opiate alkaloids in the poppy-head. Opioid alkaloids 
were extracted from the latex of poppy heads later in the 
XIXth century, among them the most important painkiller was 
morphine, a phenanthrene alkaloid. The advantage of drugs 
acting on mu-opiate receptor is, that they act not only at the 
peripheral nervous system, but they also stop the conscious-
ness of pain in the central nervous system. A lot of synthetic 
antinociceptive opioid compounds are now used in therapy, 
but they all have more or less serious side-effects during long 
application like tolerance, habituation, addiction and with-
drawal symptoms. After chronic opioid therapy withdrawal 
induces also hyperalgesia and activation of glial cells. Glial 
cells, mainly astrocytes and microglia, are activated also 
during neuropathic pain. They are able to reverse the effect 
of opioids contributing to opioid tolerance, dependence and 
withdrawal (Watkins et al.2005, 2007). The selective agonists 
of the kappa-opioid receptor (benzeneacetamidine, benzo-
morphan, cyclazocine) induce dysphoria and hypothermia. 
They are therefore not used as painkillers; nevertheless the 
Figure 2. Topological model of TRPV1 domains. PKA: proteinkinase A, CaM: calmodulin ,CAMKI, CAMKII: calmodulin kinase I and II, PIP2: 
phosphatidylinositol-diphosphate ,PKC: proteinkinase C, adapted from Caterina and Park (2006).
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thermic effect could be related with the more efficient use of 
kappa ligands against pain caused by burning. These effects 
on temperature regulation are partly antagonized by nalox-
one, some of them are naloxone resistant (Martin 1984). It is 
known, that for the painkiller activity of delta opioid agonists 
the presence of mu-opioid receptors is also essential. They 
form probable heteromers with the delta-opioid receptor to 
be more effective. According to Scherrer et al. (2009) delta 
opioid receptors are responsible for antinociception of me-
chanical and mu-opioid receptors of heat pain-killing in the 
dorsal root ganglion.
The synthesis of the endogenous cannabinod anandamide 
is catalysed by the enzymes N-acyltransferase and phospho-
lipase D in the presence of Ca2+ (Liu et al. 2008). The me-
tabolism is achieved by a fatty acid amide hydrolase (FAAH), 
resulting in arachidonic acid and ethanolamide (Cravatt et al. 
1996). The inhibition of FAAH activity increases the effect 
of anandamide (Jhaveri et al. 2006). 2-arachidonylglycerol is 
metabolized by monoacylglycerol lipase (MAGL). Genetic 
disruption of this enzyme causes elevation of MAGL in the 
brain which can lead to desensitization of cannabinoid recep-
tors (Lichtman et al. 2010). Anandamides are formed from the 
neuron membrane and they are not stored in synaptic vesicles, 
but act directly on cannabis receptors. The cannabis receptors 
are also coupled to G
i/o
 proteins like the opioid receptors. 
They have two types, CB1 which is present in the central 
nervous system and CB2 which occurs in the periphery and 
acts mainly through the immune system. The final cannabis 
action is perfected by the closing of Ca2+ ion channels and 
the opening of K+ ion channels of the cells. The physiological 
analgetic, sedative, and addictive actions of the endogenous 
cannabinoids are somewhat similar, but less strong than those 
of the opiates, however the amount of CB receptors in the 
brain is higher than those of opioid receptors (Christie 2006, 
Maldonado et al. 2006). Anandamide in higher concentrations 
is also able to activate and desensitize TRPV1 (Di Marzo et 
al. 2002, Akopian et al. 2009). Another endogenously acting 
agonist is NADA (N-arachydonoyl-dopamine), which is cited 
together with anadamide as endogenously occurring ligands 
of ‘ionotropic cannabinoid receptors‘ (i.e.TRPV-s) (Akopian 
et al.2009). Cannabinoid alkaloids are present in the plant 
Indian hemp Cannabis sativa. Among phytocannabinoids 
(about 80) the most effective is delta9-tetrahydro-cannabinol.
The plant is desiccated and pulverized, finally smoked in 
the form of cigarettes. Their introduction as analgetics is 
employed in carcinomatous patients, affective and neurode-
generative diseases (Izzo et al. 2009).
Figure 3.  Protein structure and similarity distribution among the three opioid receptors. Adapted from Chen et al. (1993). The N- and C-termini 
of each opioid receptor are marked by arrows. P: palmitoylation site. Black shading: identical among all three receptors, grey shading: identical 
in two out of three receptors, o: unique for each receptor.
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conclusions
In conclusion one can admit, that pain is a very compli-
cated category, not only from the physiological (acute) and 
pathological (chronic), but also from the molecular aspect. 
Based on this dual concept not alone should the physiologi-
cal mechanims be solved, but the pathological one, being far 
more intricate and even much more distant to clear up. The 
new concept of genomics and proteomics could be extended 
quite well on pain as painomics (painomix?). Nevertheless the 
scientific effort put in this important symptom for mankind 
should go further until it is solved. 
   Beside physical pain, psychical suffering might also be a 
tormenting factor of the pain syndrome, but even less molecu-
lar events are known compared with the somatic symptoms, 
yet a disorder in the metabolism of brain neurotransmitters 
(serotonin, dopamine) are supposed to be a cause or conse-
quence of it.
   Among the greatest writers, Dante Alighieri character-
ized this sort of pain in his Divina Commedia with the follow-
ing lines: ‘Nessun maggior dolore che ricordarsi del tempo 
felice nella miseria’ (There is no greater pain to remember 
a happy time when one is in misery) Inferno, Canto V. linea 
121-123.
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